Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
+0.91 (2.77%)
After Hours: 33.73 +0.02 (0.06%)
May 3, 6:27PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 33.25 - 33.97
52 week 28.25 - 36.46
Open 33.65
Vol / Avg. 71.53M/50.92M
Mkt cap 209.30B
P/E 30.33
Div/yield 0.30/3.56
EPS 1.11
Shares 6.19B
Beta 0.84
Inst. own 74%
May 3, 2016
Q1 2016 Pfizer Inc Earnings Call
May 3, 2016
Q1 2016 Pfizer Inc Earnings Release
Apr 28, 2016
Pfizer Inc Annual Shareholders Meeting
Apr 22, 2016
Pfizer Inc Annual Shareholders Meeting (Estimated)
Mar 8, 2016
Pfizer Inc at Cowen Health Care Conference
Mar 3, 2016
Pfizer Inc at Deutsche Bank Pharma One-on-One Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -1.19% 14.28%
Operating margin -0.23% 21.14%
EBITD margin - 38.46%
Return on average assets -0.40% 4.16%
Return on average equity -1.03% 10.22%
Employees 97,900 -
CDP Score - 90 B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel. Its commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business consists of two segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 58
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business, Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 57
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 51
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 54
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 60
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Anthony J. Maddaluna Executive Vice President, President - Pfizer Global Supply
Age: 63
Bio & Compensation  - Reuters